Month: March 2020

VANCOUVER, British Columbia, March 30, 2020 (GLOBE NEWSWIRE) — Eldorado Gold Corporation, (“Eldorado” or “the Company”) reports that it has drawn $150 million under its revolving credit facility as a proactive measure in light of the uncertainty surrounding the COVID-19 pandemic. The Company has no immediate need for the funds, however proceeds will be used for general corporate purposes, as required. The Company is also reviewing its 2020 sustaining and growth capital budget and will reduce expenditures if required.The monies have been drawndown under the Company’s $450 million Third Amended and Restated Senior Credit Facility dated June 5, 2019. The applicable interest rate on the funds is a function of the Company’s net leverage ratio as at the last day of the most recently completed fiscal quarter and is based on the London...

LiiteINVEST_30.3_trades

AttachmentGOFORE_30.3_trades

LiiteGOFORE_30.3_trades

LiiteSCANFIL_30.3_trades

AttachmentSCANFIL_30.3_trades

ORION CORPORATION PRESS RELEASE 30 MARCH 2020 at 18.15 EEST             Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer         The European Commission has granted marketing authorisation in the European Union (EU) for Nubeqa® (darolutamide), an oral androgen receptor inhibitor (ARi). The approval is based on Phase III ARAMIS trial results showing a statistically significant improvement in metastasis-free survival (MFS) for darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT, and a favorable safety profile.The compound, which is developed jointly by Orion Corporation and Bayer, is indicated for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease....

ORION OYJ LEHDISTÖTIEDOTE 30.3.2020 klo 18.15                      Nubeqa®-lääkkeelle (darolutamidi) myyntilupa EU:ssa etäpesäkkeettömän, hormonaaliselle hoidolle vastustuskykyisen eturauhassyövän uutena hoitonaEuroopan komissio on myöntänyt myyntiluvan Euroopan Unionissa Nubeqa®-lääkkeelle (darolutamidi), joka on suun kautta otettava androgeenireseptorin estäjä. Hyväksyntä perustuu III-vaiheen ARAMIS-tutkimukseen, jossa darolutamidin ja tavanomaisen hormonaalisen hoidon (androgeenideprivaatioterapia, ADT) yhdistelmän osoitettiin pidentävän erittäin merkitsevästi etäpesäkkeetöntä elinaikaa verrattuna lumelääkkeen ja tavanomaisen hoidon yhdistelmään. Lisäksi tutkimus osoitti darolutamidin turvallisuusprofiilin olevan suotuisa.Orionin ja Bayerin yhdessä kehittämä lääke on tarkoitettu etäpesäkkeettömän, hormonaaliselle hoidolle vastustuskykyisen...

Tryg’s annual general meeting (AGM) was held today. At the AGM, the shareholders adopted the report of the group’s activities in the financial year 2019.The annual meeting also approved the following items:• Tryg’s annual report 2019, including the resolution on discharge of the Executive Board and the Supervisory Board.• Resolution to distribution of profits in accordance with the approved annual report as the profit for the year DKK 2,843m is transferred to the equity.• The proposed remuneration for the Supervisory Board for 2020 including the fees to members of the Supervisory Board committees.• The proposed renewal and extension of the existing authorisation to the Supervisory Board under Article 8 of the Articles of Association to increase the share capital by means of issuing new shares for a total face value of DKK 151,000,000...